THE UNIVERSITY OF TOKYO;TAKAHIRO NAKAMURA;HIROTAKA MATSUO;TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES;NARIYOSHI SHINOMIYA
发明人:
HIROTAKA MATSUO,Nariyoshi Shinomiya,Takahiro Nakamura,Tappei Takada,Hiroshi Suzuki,Yuki Ikebuchi,Kousei Ito,Kimiyoshi Ichida
申请号：
US15486788
公开号：
US20170218451A1
申请日:
2017.04.13
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Methods of treating, or at least inhibiting the onset of, urate transport failure are provided. The methods can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
